ECU
DNLI icon

Eisler Capital (US)’s Denali Therapeutics DNLI Stock Holding History

Eisler Capital (US)’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-35,861
Closed -$833K – 524
2024
Q2 		$833K Buy
35,861
+1,381
+4% +$26.5K 0.01% 479
2024
Q1 		$708K Buy
+34,480
New +$648K 0.02% 449

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Eisler Capital (US)'s DNLI Position: Q3 2024 in Review

Eisler Capital (US) sold out of Denali Therapeutics (DNLI) in Q3 2024, closing a stake of 35,861 shares — an estimated $833K sold.

Eisler Capital (US) first reported a position in DNLI in Q1 2024 and held it in 2 quarters. The position peaked at $833K in Q2 2024. 217 funds tracked by Wall St. Rank hold DNLI as of Q3 2024.

  • Eisler Capital (US) reported no remaining Denali Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Eisler Capital (US) sold 35,861 Denali Therapeutics shares in Q3 2024, an estimated $833K.
  • Eisler Capital (US) first reported a position in Denali Therapeutics in Q1 2024 and held it in 2 quarters.
  • Eisler Capital (US)'s Denali Therapeutics position peaked at $833K in Q2 2024.
  • 217 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2024.

Based on Eisler Capital (US)'s 13F filing for Q3 2024, filed 14 Nov 2024.